In addition to eliciting immune responses against pathogens, the delivery of tumor-associated antigens (such as tyrosinase-related protein 2) or other antigens known to be involved in tumorigenesis (such as survivin) to DEC-205-expressing cells in the presence of co-administered adjuvants, such as CpG, Poly(I:C), or anti-CD40, enhanced the anti-tumor CD4+ and CD8+ T cell responses and decreased the tumor burden [57,58,59,60,61,75,76]. The gene discussed is CD4; the disease is neoplasm.